Genetic Testing to Understand and Address Renal Disease Disparities Across the United States Pharmacogenetic Substudy

NACompletedINTERVENTIONAL
Enrollment

1,874

Participants

Timeline

Start Date

July 10, 2020

Primary Completion Date

April 9, 2024

Study Completion Date

May 17, 2024

Conditions
Chronic Kidney DiseaseHypertension
Interventions
OTHER

Timing of return of results

Participants will be randomized to immediate versus delayed return of PGx results.

Trial Locations (8)

10029

Icahn School of Medicine at Mount Sinai, New York

10035

The Institute for Family Health, New York

15261

University of Pittsburgh, Pittsburgh

32209

University of Florida - Jacksonville, Jacksonville

32610

University of Florida - Gainesville, Gainesville

35294

University of Alabama at Birmingham, Birmingham

46202

Eskenazi Health, Indianapolis

Indiana University, Indianapolis

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Human Genome Research Institute (NHGRI)

NIH

collaborator

Icahn School of Medicine at Mount Sinai

OTHER

collaborator

University of Florida

OTHER

collaborator

Indiana University School of Medicine

OTHER

lead

Duke University

OTHER

NCT06748040 - Genetic Testing to Understand and Address Renal Disease Disparities Across the United States Pharmacogenetic Substudy | Biotech Hunter | Biotech Hunter